Supplementary Table S4. Literature Review - Efficacy Outcomes by MRD Log-Group for B-cell ALL CR1 Using End-Of-Induction MRD Measurements from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease